Featured Research

from universities, journals, and other organizations

‘Cornell dots’ that light up cancer cells go into clinical trials

Date:
February 7, 2011
Source:
Cornell University
Summary:
"Cornell Dots" -- brightly glowing nanoparticles -- may soon be used to light up cancer cells to aid in diagnosing and treating cancer. The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of the new technology. It is the first time the FDA has approved using an inorganic material in the same fashion as a drug in humans.

Ulrich Wiesner, left, works with graduate students Jennifer Drewes and Kai Ma to characterize the size and brightness of C dots in their Bard Hall lab.
Credit: Jason Koski/University Photography

"Cornell Dots" -- brightly glowing nanoparticles -- may soon be used to light up cancer cells to aid in diagnosing and treating cancer. The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of the new technology. It is the first time the FDA has approved using an inorganic material in the same fashion as a drug in humans.

"The FDA approval finally puts a federal approval stamp on all the assumptions we have been working under for years. This is really, really nice," said Ulrich Wiesner, the Spencer T. Olin Professor of Materials Science and Engineering, who has devoted eight years of research to developing the nanoparticles. "Cancer is a terrible disease, and my family has a long history of it. I, thus, have a particular personal motivation to work in this area."

The trial with five melanoma patients at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City will seek to verify that the dots, also known as C dots, are safe and effective in humans, and to provide data to guide future applications. "This is the first product of its kind. We want to make sure it does what we expect it to do," said Michelle Bradbury, M.D., radiologist at MSKCC and assistant professor of radiology at Weill Cornell Medical College.

C dots are silica spheres less than 8 nanometers in diameter that enclose several dye molecules. (A nanometer is one-billionth of a meter, about the length of three atoms in a row.) The silica shell, essentially glass, is chemically inert and small enough to pass through the body and out in the urine. For clinical applications, the dots are coated with polyethylene glycol so the body will not recognize them as foreign substances.

To make the dots stick to tumor cells, organic molecules that bind to tumor surfaces or even specific locations within tumors can be attached to the shell. When exposed to near-infrared light, the dots fluoresce much brighter than unencapsulated dye to serve as a beacon to identify the target cells. The technology, the researchers say, can show the extent of a tumor's blood vessels, cell death, treatment response and invasive or metastatic spread to lymph nodes and distant organs. The safety and ability to be cleared from the body by the kidneys has been confirmed by studies in mice at MSKCC, reported in the January 2009 issue of the journal Nano Letters (Vol. 9 No. 1).

For the human trials, the dots will be labeled with radioactive iodine, which makes them visible in PET scans to show how many dots are taken up by tumors and where else in the body they go and for how long.

"We do expect it to go to other organs," Bradbury said. "We get numbers, and from that curve derive how much dose each organ gets. And we need to find out how fast it passes through. Are they cleared from the kidney at the same rate as in mice?"

One of many advantages of C dots, Bradbury noted, is that they remain in the body long enough for surgery to be completed. "Surgeons love optical," she said. "They don't need the radioactivity, but [our study] confirms what the optical signal is. As you learn that, eventually you no longer need the radioactivity."

On the other hand, she added, the dots also may serve as a carrier to deliver radioactivity or drugs to tumors. "This is step one to jump-start a process we think will do multiple things with one platform," she said.

First-generation Cornell dots were developed in 2005 by Hooisweng Ow, then a graduate student working with Wiesner. Wiesner, Ow and Kenneth Wang '77 have co-founded the company Hybrid Silica Technologies to commercialize the invention. The dots, Wiesner said, also have possible applications in displays, optical computing, sensors and such microarrays as DNA chips.

Wiesner's original research was funded by the National Science Foundation, New York state and Phillip Morris USA.


Story Source:

The above story is based on materials provided by Cornell University. Note: Materials may be edited for content and length.


Cite This Page:

Cornell University. "‘Cornell dots’ that light up cancer cells go into clinical trials." ScienceDaily. ScienceDaily, 7 February 2011. <www.sciencedaily.com/releases/2011/02/110205162831.htm>.
Cornell University. (2011, February 7). ‘Cornell dots’ that light up cancer cells go into clinical trials. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2011/02/110205162831.htm
Cornell University. "‘Cornell dots’ that light up cancer cells go into clinical trials." ScienceDaily. www.sciencedaily.com/releases/2011/02/110205162831.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins